Procter & Gamble’s Novel Fully Injection-Molded Polypropylene Nasal Swab Improves Speed of COVID-19 Testing
By LabMedica International staff writers Posted on 25 Jan 2021 |

Image: Rhinostics Standard Nasal Swab (Photo courtesy of Business Wire)
A novel polypropylene nasal swab developed for COVID-19 testing that allows for easy collection from the front of the nose and provides sample concentration of up to 30 fold over other swabs in viral transport media is likely to positively impact testing availability.
Procter & Gamble (P&G; Cincinnati, OH, USA) and Rhinostics Inc. (Cambridge, MA, USA), a Harvard spin-out company, have partnered to develop the nasal swab that improves the speed of testing and adds additional swab capacity for COVID-19 testing. The fully injection-molded polypropylene nasal swab has been developed by iMFLUX, a subsidiary of P&G, which is licensing its novel nasal swab to Rhinostics to launch and bring to the clinical laboratory market.
P&G developed the swab as part of its commitment to help communities address supply shortages and to bring creative solutions to bear on the challenges facing laboratories and supply chains during the COVID-19 pandemic. The project was a collaboration between resources from P&G’s Personal Health Care business and iMFLUX, a subsidiary focused on mold design and process technology innovation for the plastics injection molding market. Swabs continue to be in short supply and are critical to fighting the COVID-19 pandemic. The companies believe the nasal swab’s unique features make it a better material choice for both PCR and antigen-based assays. These swabs reduce handling and lab processing cycle time and increase lab capacity as new home collection kits expand rapidly into the virus detection market.
Rhinostics plans on registering the P&G polypropylene nasal swab as a Class I Exempt medical device and will pursue Emergency Use Authorization for home collection with rPT-PCR testing, the gold standard for detection of SARS-CoV-2 infection. This licensing agreement has the potential to provide relief to the constrained market, expedite test results and be a solution for future testing needs, like influenza.
“We are proud to see the P&G developed nasal swab come to market through Rhinostics efforts. When we began this program, our intention was simply to help relieve bottlenecks in COVID-19 swab supply and bring a novel collection device to bear on the problem,” said Mary Wagner, SVP at P&G and CEO of iMFLUX.
“P&G and iMFLUX have been vital partners in helping Rhinostics launch the manufacturing of its nasal swab collection products. We believe there is a significant opportunity to bring new collection devices like the P&G nasal swab to clinical laboratory workflow. Not only does the nasal swab production help to relieve supply chain bottlenecks, the new design and polypropylene materials allows for comfortable collection and sample concentration due to dry shipment and improved release of viral particles. We are excited to bring this innovation to the clinical laboratory market,” says Cheri Walker, Chief Executive Officer of Rhinostics, “We look forward to continuing to work with the iMFLUX team to develop molds across our product lines.”
Related Links:
Procter & Gamble
Rhinostics Inc.
Procter & Gamble (P&G; Cincinnati, OH, USA) and Rhinostics Inc. (Cambridge, MA, USA), a Harvard spin-out company, have partnered to develop the nasal swab that improves the speed of testing and adds additional swab capacity for COVID-19 testing. The fully injection-molded polypropylene nasal swab has been developed by iMFLUX, a subsidiary of P&G, which is licensing its novel nasal swab to Rhinostics to launch and bring to the clinical laboratory market.
P&G developed the swab as part of its commitment to help communities address supply shortages and to bring creative solutions to bear on the challenges facing laboratories and supply chains during the COVID-19 pandemic. The project was a collaboration between resources from P&G’s Personal Health Care business and iMFLUX, a subsidiary focused on mold design and process technology innovation for the plastics injection molding market. Swabs continue to be in short supply and are critical to fighting the COVID-19 pandemic. The companies believe the nasal swab’s unique features make it a better material choice for both PCR and antigen-based assays. These swabs reduce handling and lab processing cycle time and increase lab capacity as new home collection kits expand rapidly into the virus detection market.
Rhinostics plans on registering the P&G polypropylene nasal swab as a Class I Exempt medical device and will pursue Emergency Use Authorization for home collection with rPT-PCR testing, the gold standard for detection of SARS-CoV-2 infection. This licensing agreement has the potential to provide relief to the constrained market, expedite test results and be a solution for future testing needs, like influenza.
“We are proud to see the P&G developed nasal swab come to market through Rhinostics efforts. When we began this program, our intention was simply to help relieve bottlenecks in COVID-19 swab supply and bring a novel collection device to bear on the problem,” said Mary Wagner, SVP at P&G and CEO of iMFLUX.
“P&G and iMFLUX have been vital partners in helping Rhinostics launch the manufacturing of its nasal swab collection products. We believe there is a significant opportunity to bring new collection devices like the P&G nasal swab to clinical laboratory workflow. Not only does the nasal swab production help to relieve supply chain bottlenecks, the new design and polypropylene materials allows for comfortable collection and sample concentration due to dry shipment and improved release of viral particles. We are excited to bring this innovation to the clinical laboratory market,” says Cheri Walker, Chief Executive Officer of Rhinostics, “We look forward to continuing to work with the iMFLUX team to develop molds across our product lines.”
Related Links:
Procter & Gamble
Rhinostics Inc.
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
Accurately monitoring drug levels in the blood is essential for effective treatment, particularly in the management of cardiovascular diseases. Traditional techniques for monitoring blood drug levels often... Read more
Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
Timely and accurate monitoring of renal function is essential for managing patients at risk of acute kidney injury (AKI), which affects about 12% of hospitalized patients and up to 57% of ICU patients.... Read more
Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
Nanopores are tiny openings that can detect individual molecules as they pass through, making them ideal for analyzing biomolecules like DNA and proteins. However, detecting proteins at extremely low ... Read moreMolecular Diagnostics
view channel
Portable Blood-Based Device Detects Colon Cancer
Colon cancer is the second leading cause of cancer-related deaths in the U.S., yet it is highly treatable when detected at an early stage. Traditional colonoscopy screenings, although effective, are unpleasant,... Read more
New DNA Test Diagnoses Bacterial Infections Faster and More Accurately
Antimicrobial resistance has emerged as a significant global health threat, causing at least one million deaths annually since 1990. The Global Research on Antimicrobial Resistance (GRAM) Project warns... Read more
Innovative Bio-Detection Platform Improves Early Cancer Screening and Monitoring
Cancer remains one of the leading causes of death globally, underscoring the critical need for more advanced, efficient, and early detection methods. Circulating tumor cells (CTCs) are cells that have... Read more
Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer
Cancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. However, this survival rate dramatically decreases to just 30% when the cancer... Read moreHematology
view channel
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
WBC Count Could Predict Severity of COVID-19 Symptoms
The global health crisis caused by the SARS-CoV-2 virus continues to impact millions of people worldwide, with many experiencing persistent symptoms months after the initial diagnosis. Cognitive impairment... Read more
New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
Accurate platelet count testing is a significant challenge for laboratories. Inaccurate results can lead to misdiagnosis, missed diagnoses, and delayed treatment for a variety of potentially fatal conditions,... Read more
Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
Heparin-induced thrombocytopenia (HIT), a serious side effect of the blood thinner heparin, is difficult to diagnose because thrombocytopenia, or low platelet count, can be caused by a variety of factors... Read moreImmunology
view channelCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read more
Rapid PCR Testing in ICU Improves Antibiotic Stewardship
A collaborative study led by the University of Plymouth (Devon, UK) has shown that rapid polymerase chain reaction (PCR) testing in the intensive care unit (ICU) improved antibiotic stewardship compared... Read morePathology
view channel
New Test Diagnoses High-Risk Childhood Brain Tumors
Medulloblastoma, which originates in the cerebellum, the rear part of the brain, is the most prevalent malignant brain tumor in children and is notoriously difficult to diagnose. Currently, identifying... Read more
Informatics Solution Elevates Laboratory Efficiency and Patient Care
QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread
Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis
Tissue analysis typically involves a pathologist reviewing scanned digital slides from a patient’s intestinal sample and marking specific areas, such as those where cancerous and related tissues are present.... Read moreTechnology
view channel
POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
Cardiovascular diseases continue to be the leading cause of death worldwide, accounting for over 19 million fatalities annually. Early detection of myocardial infarction (MI), commonly known as a heart... Read more
Study Explores Impact of POC Testing on Future of Diagnostics
In today’s rapidly changing world, having quick and accurate access to medical information is more crucial than ever. Point-of-Care Diagnostics (PoC-D) and Point-of-Care Testing (PoC-T) are making this... Read more
Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
Cancer biomarkers are valuable tools for early diagnosis as their concentration in body fluids, such as serum, can be measured to detect the disease at an earlier stage. Additionally, serum levels of these... Read moreIndustry
view channel
CACLP 2025 Unites Global Innovators in IVD Industry
CACLP (Shanghai, China) will be holding the 22nd China International In Vitro Diagnostic Expo, the largest and most influential gathering of the IVD industry in China, 22-24 March 2025 at the Hangzhou... Read more
Bio-Rad to Acquire Digital PCR Developer Stilla Technologies
Bio-Rad Laboratories (Hercules, CA, USA) has entered into a binding offer to purchase all equity interests in Stilla Technologies (Villejuif, France). The acquisition remains subject to consultation with... Read more